ATE275629T1 - Genexpressions-basensequenzen zur therapeutischen anwendung und heilmittel zur gentherapie - Google Patents

Genexpressions-basensequenzen zur therapeutischen anwendung und heilmittel zur gentherapie

Info

Publication number
ATE275629T1
ATE275629T1 AT00913045T AT00913045T ATE275629T1 AT E275629 T1 ATE275629 T1 AT E275629T1 AT 00913045 T AT00913045 T AT 00913045T AT 00913045 T AT00913045 T AT 00913045T AT E275629 T1 ATE275629 T1 AT E275629T1
Authority
AT
Austria
Prior art keywords
gene
remedies
base sequences
therapeutic use
base sequence
Prior art date
Application number
AT00913045T
Other languages
English (en)
Inventor
Kazuhiro Yuda
Katsuhiko Akiyama
Takeshi Goto
Katsuyuki Hamada
Original Assignee
Hisamitsu Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisamitsu Pharmaceutical Co filed Critical Hisamitsu Pharmaceutical Co
Application granted granted Critical
Publication of ATE275629T1 publication Critical patent/ATE275629T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4731—Recognins, e.g. malignin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00913045T 1999-04-02 2000-03-31 Genexpressions-basensequenzen zur therapeutischen anwendung und heilmittel zur gentherapie ATE275629T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9635899 1999-04-02
PCT/JP2000/002102 WO2000060068A1 (fr) 1999-04-02 2000-03-31 Sequences de bases d'expression genique utilisees a des fins therapeutiques et medicaments utilises en therapie genique

Publications (1)

Publication Number Publication Date
ATE275629T1 true ATE275629T1 (de) 2004-09-15

Family

ID=14162782

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00913045T ATE275629T1 (de) 1999-04-02 2000-03-31 Genexpressions-basensequenzen zur therapeutischen anwendung und heilmittel zur gentherapie

Country Status (7)

Country Link
US (1) US6815430B1 (de)
EP (1) EP1174501B1 (de)
KR (1) KR100636578B1 (de)
AT (1) ATE275629T1 (de)
CA (1) CA2365545A1 (de)
DE (1) DE60013586T2 (de)
WO (1) WO2000060068A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5858601B2 (ja) * 2010-08-24 2016-02-10 花王株式会社 シミ関連遺伝子

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5728379A (en) * 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
DE19525900C1 (de) 1995-07-15 1996-12-12 Max Planck Gesellschaft Leberspezifischer Adenovirus-Expressionsvektor
JPH0928378A (ja) 1995-07-17 1997-02-04 Soosei:Kk 神経細胞特異的に発現するアデノウイルスベクター
GB9616685D0 (en) 1995-10-02 1996-09-25 Cancer Res Campaign Tech Antitumour vector constructs and methods
DE19704301C1 (de) 1997-02-06 1998-03-26 Hoechst Ag Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie
EP0893493A3 (de) 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen

Also Published As

Publication number Publication date
EP1174501A1 (de) 2002-01-23
DE60013586D1 (de) 2004-10-14
EP1174501B1 (de) 2004-09-08
KR100636578B1 (ko) 2006-10-19
US6815430B1 (en) 2004-11-09
CA2365545A1 (en) 2000-10-12
KR20010112930A (ko) 2001-12-22
DE60013586T2 (de) 2005-02-03
WO2000060068A1 (fr) 2000-10-12
EP1174501A4 (de) 2002-07-03

Similar Documents

Publication Publication Date Title
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
HK1026691A1 (en) Substituted benzimidazoles and their use for treating retroviral infection
PT1042305E (pt) Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas
AU2001290837A1 (en) Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
PT710114E (pt) Formulacao do factor viii de coagulacao
DE60118382D1 (de) Protoonkogen aus menschlichem zervixkarzinom 2 und davon codiertes protein
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69328025D1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
DE60237791D1 (de) Zytokinproteinfamilie
ATE391186T1 (de) Gezielte verabreichung von kuenstlichen genen
LV11728A (lv) Farmaceitiska kompozicija
ATE275629T1 (de) Genexpressions-basensequenzen zur therapeutischen anwendung und heilmittel zur gentherapie
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
ATE504309T1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
Cadoni et al. Endoscopic treatment of a duodeno-cutaneous fistula with fibrin tissue sealant (TISSUCOL)
SE9700244D0 (sv) Novel antibacterial protein
ES2187557T3 (es) Utilizacion de dextrano sustituido para el tratamiento de las lesiones del sistema nervioso y fracciones enriquecidas en heparano sulfato.
DE60140950D1 (de) Neuer gentherapeutischer wirkstoff zur behandlung g
KR950702838A (ko) 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4)
BR0206918A (pt) Uso de iloperidona
DK1007085T3 (da) Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet
NZ505350A (en) DNA encoding a tumour antigen peptide (43 kDa) for diagnosis or treatment of tumours

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties